Stop missing out on important events!
Latest Activist 13D and 13G Filings
Every investor that acquires 5% of a company is required to file a beneficial ownership filing, which is either a Form 13D or Form 13G, within ten (10) days of the event. If the investor intends to influence management, then they are considered an activist investor and must file a 13D. There is evidence that suggests investing alongside activist investors is a stock market investing strategy that can produce excess returns. This free screener shows all of the required Schedule 13D filings made by activist investors.
|2018‑04‑26||SC 13D||CLBK / Columbia Financial||Columbia Bank Mhc||62,580,155||54.0|
|2018‑04‑26||SC 13D/A||CIK / Credit Suisse Asset Management Income Fund||Saba Capital Management, L.P.||3,701,358||13.0|
|2018‑04‑26||SC 13D/A||USG / USG||Gebr. Knauf Verwaltungsgesellschaft Kg||14,757,258||10.53|
|2018‑04‑26||SC 13D/A||DB / Deutsche Bank||C-QUADRAT Special Situations Dedicated Fund||164,489,635||8.0|
|2018‑04‑26||SC 13D/A||DRAD / Digirad||CANNELL CAPITAL LLC||2,161,742||10.76|
|2018‑04‑25||SC 13D||RTTO / Rito Group||China South Telecom Group Co Ltd||100,000||0.18|
|2018‑04‑25||SC 13D/A||LAUR / LAUREATE EDUCATION||SPG GP, LLC||4,915,991||2.3|
|2018‑04‑25||SC 13D||SENS / Senseonics Holdings||SMITH ROBERT J||13,629,339|
|2018‑04‑25||SC 13D/A||LAUR / LAUREATE EDUCATION||Point72 Asset Management, L.P.||126,199,174||58.0|
|2018‑04‑25||SC 13D||RTTO / Rito Group||Rito Group Holding Ltd||36,200,000||65.33|
Latest Research Reports
Fintel Research Reports are free Wikipedia-style reports that are created and edited by people just like you. If you are an expert on a company and would like to help your fellow investors make more informed investing decisions, then you should become a Fintel Contributing Analyst. To do this, register on the site, message us in the online chat, and we will get you started.
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
Stock screens allow users to filter the companies listed on the stock market by various attributse, in order to screen out those that are undesirable. Stock screens on Fintel are made from a rich formula language that allows the utmost flexibility.
Financial Charts by Fintel.io
Top Institutional Investors
|Vanguard Group Inc|
|FMR LLC / Fidelity|
|BlackRock Fund Advisors|
|Capital World Investors|
|Capital Research Global Investors|
|Berkshire Hathaway Inc||Warren Buffett|
|Renaissance Technologies LLC||James Simons|
|Third Point LLC||Dan Loeb|
|Tiger Global Management Llc||Chase Coleman, Feroz Dewan|
|Baker Brothers Advisors LP||Julian and Felix Baker|
|Melvin Capital Management LP||Gabriel Plotkin|
|Baupost Group LLC/MA||Seth Klarman|
|ValueAct Holdings, L.P.||Jeff Ubben|
|Gotham Asset Management, LLC||Joel Greenblatt|
|Pershing Square Capital Management, L.P.||Bill Ackman|
|GreenLight Capital Inc||David Einhorn|
|Starboard Value LP||Jeffrey Smith|
|Hitchwood Capital Management LP||James Warby Crichton|
|Duquesne Family Office LLC||Stanley Druckenmiller|
|Sabby Management, LLC||Hal David Mintz|
|Pine River Capital Management L.P.||Brian Taylor and James Clark|
|Bodenholm Capital AB|
|Scion Asset Management, LLC||Dr. Michael Burry|